Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 19/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894543 | 1.00 | CXCR3 (0.59) | CXCR3CYP3A4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL14178881 | 0.92 | CXCR3 (0.52) | CXCR3CYP3A4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL12659743 | 0.90 | CXCR3 (0.54) | CXCR3CYP3A4 | |
| SCHEMBL1895439 | 0.89 | PIK3CD (0.48) | CXCR3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1895441 | 0.89 | PIK3CD (0.48) | CXCR3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12659732 | 0.81 | PIK3CD (0.48) | CXCR3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14178906 | 0.81 | CXCR3 (0.47) | CXCR3CYP3A4 | |
| SCHEMBL12659730 | 0.81 | CXCR3 (0.53) | CXCR3CYP3A4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1886849 | 0.79 | CXCR3 (0.45) | CXCR3CYP3A4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1886850 | 0.79 | CXCR3 (0.45) | CXCR3CYP3A4PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939538-B2 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7375102-B2 | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use | AMGEN SF, LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20060069106-A1 | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use | AMGEN SF, LLC | 2006-03-30 | — | — | US | disclosed |
| US-20060069099-A1 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN SF, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069099-A1 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | MSR1, TNF, HLA-DRB1 | CXCR3 85/4885CYP3A4 1459/4885PIK3CD 4073/4885 |
| US-20060069106-A1 | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use | IFNG, IRF3, TBXA2R | CXCR3 10/4885CYP3A4 326/4885PIK3CD 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.